NeuroScientific Biopharmaceuticals Limited
NeuroScientific Biopharmaceuticals Limited
Your view on NSB.AX
Overview
What the company does, where it operates, and who runs it.
About NeuroScientific Biopharmaceuticals Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Nathan Smith
- Headquarters
- 216 St Georges Terrace, Perth, WA, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Nathan Smith
- Headquarters
- 216 St Georges Terrace, Perth, WA, AU
Established in 2002 and headquartered in Cottesloe, Australia, NeuroScientific Biopharmaceuticals Limited specializes in the development of medical therapies for neurodegenerative conditions. The company conducts extensive preclinical and clinical research utilizing its proprietary technological platforms to advance these treatments.
Its primary pharmaceutical compound, EmtinB, is being developed as a potential therapeutic agent for diseases including neurodegenerative dementia, Alzheimer's disease, and various degenerative disorders affecting the optic nerve.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for NeuroScientific Biopharmaceuticals Limited. Starting points for NeuroScientific Biopharmaceuticals Limited: EPS -AUD 0.01, beta 1.12 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for NeuroScientific Biopharmaceuticals Limited. NeuroScientific Biopharmaceuticals Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for NeuroScientific Biopharmaceuticals Limited. Trailing twelve-month EPS for NeuroScientific Biopharmaceuticals Limited stands at -AUD 0.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for NeuroScientific Biopharmaceuticals Limited. NeuroScientific Biopharmaceuticals Limited has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| OSRHWOSR Holdings, Inc. | Healthcare | NASDAQ | $7.8M | ||
| OSTXOS Therapies Incorporated | Healthcare | AMEX | $42.0M | ||
| OTLCOncotelic Therapeutics, Inc. | Healthcare | OTC | $21.2M | ||
| OTLKOutlook Therapeutics, Inc. | Healthcare | NASDAQ | $94.9M | ||
| OVIDOvid Therapeutics Inc. | Healthcare | NASDAQ | $415.2M | ||
| OXBOFOxford BioDynamics Plc | Healthcare | OTC | $4.3M | ||
| OZYMFStrategic Partners A/S | Healthcare | OTC | $3.7M | ||
| PAB.AXPatrys Limited | Healthcare | ASX | — | ||
| PALIPalisade Bio, Inc. | Healthcare | NASDAQ | $150.6M | ||
| PANCPanacos Pharmaceuticals, Inc. | Healthcare | OTC | $5,367 | ||
| PAR.AXParadigm Biopharmaceuticals Limited | Healthcare | ASX | — | ||
| PARDPoniard Pharmaceuticals, Inc. | Healthcare | OTC | $150 | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for NeuroScientific Biopharmaceuticals Limited. Coverage tracks NeuroScientific Biopharmaceuticals Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of NeuroScientific Biopharmaceuticals Limited.